Huperzine A clinical trials
Huperzine A is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is Wanbangde Pharmaceutical Group Co., LTD (3). The most-studied condition is Alzheimer Dementia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Huperzine A works
All drug targets →- Acetylcholinesterase inhibitor InhibitorTarget: ACHE acetylcholinesterase (Yt blood group)✓ In ChEMBL and the Guide to Pharmacology
- Cocaine abusePhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL395280, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13727, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Huperzine A
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Huperzine A
- ChEMBL
- CHEMBL395280
- DrugBank
- DB04864
- PubChem CID
- 854026
- CAS number
- 102518-79-6
- FDA UNII
- 0111871I23
- Wikidata
- Q425198
- Wikipedia
- Huperzine A
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Huperzine A
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Huperzine A in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Huperzine A. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures
2026-526361-15-00 · CTIS ↗ · Nervous System Diseases
|
Phase 2 | Authorised | Supernus Pharmaceuticals Inc | Poland, Bulgaria, Hungary |
Conditions studied with Huperzine A
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Wanbangde Pharmaceutical Group Co., LTD | 3 |
| Second Affiliated Hospital of Wenzhou Medical University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about Huperzine A trials
How many clinical trials are testing Huperzine A?
4 current trials in our China register name Huperzine A as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Huperzine A trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Huperzine A clinical trials?
Wanbangde Pharmaceutical Group Co., LTD (3) and Second Affiliated Hospital of Wenzhou Medical University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Huperzine A works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Huperzine A works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Huperzine A (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.